ProMIS Neurosciences (NASDAQ:PMN) Now Covered by Maxim Group

Stock analysts at Maxim Group assumed coverage on shares of ProMIS Neurosciences (NASDAQ:PMN) in a note issued to investors on Monday,Benzinga reports. The firm set a “buy” rating and a $3.00 price target on the stock.

Separately, Guggenheim restated a “buy” rating and issued a $6.00 price objective on shares of ProMIS Neurosciences in a research note on Tuesday, April 1st.

ProMIS Neurosciences Stock Performance

NASDAQ:PMN opened at $0.50 on Monday. The stock has a market capitalization of $16.22 million, a P/E ratio of -4.96 and a beta of 0.02. The company has a 50 day moving average price of $0.65 and a 200 day moving average price of $0.84. ProMIS Neurosciences has a fifty-two week low of $0.47 and a fifty-two week high of $2.37.

ProMIS Neurosciences (NASDAQ:PMN) last released its earnings results on Monday, May 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). Research analysts forecast that ProMIS Neurosciences will post -0.24 earnings per share for the current fiscal year.

Institutional Trading of ProMIS Neurosciences

A hedge fund recently bought a new stake in ProMIS Neurosciences stock. Allostery Investments LP acquired a new stake in ProMIS Neurosciences, Inc. (NASDAQ:PMN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 195,111 shares of the company’s stock, valued at approximately $185,000. Allostery Investments LP owned about 0.60% of ProMIS Neurosciences at the end of the most recent reporting period. 50.13% of the stock is owned by institutional investors and hedge funds.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.